InNexus Biotechnology, Inc.
IXSBF
$0.00
$0.000.00%
OTC PK
| 03/31/2011 | 12/31/2010 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.06% | 17.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.86% | 19.24% | |||
| Operating Income | 22.86% | -19.24% | |||
| Income Before Tax | 28.60% | 15.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.60% | 15.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.60% | 15.72% | |||
| EBIT | 22.86% | -19.24% | |||
| EBITDA | 37.54% | -27.71% | |||
| EPS Basic | 35.19% | 26.03% | |||
| Normalized Basic EPS | 35.29% | 24.44% | |||
| EPS Diluted | 35.19% | 26.03% | |||
| Normalized Diluted EPS | 35.29% | 24.44% | |||
| Average Basic Shares Outstanding | 11.35% | 13.63% | |||
| Average Diluted Shares Outstanding | 11.35% | 13.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||